Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer

NCT00511459 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00511459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00511459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
May 31, 2014
Enrollment
228 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

locally recurrent and metastatic breast cancer